"As with all Calmare unsubstantiated claims, Until I see written specific evidence, no one is compensating claims."
I get it, you came back to the board that you were kicked off and now you're playing God.
Unless I see written evidence the sun is coming up tomorrow it's not coming up.
Try this evidence:
Scrambler Therapy May Relieve Chronic
Neuropathic Pain More Effectively Than
Guideline-Based Drug Management: Results
of a Pilot, Randomized, Controlled Trial
Giuseppe Marineo, PhD, Vittorio Iorno, MD, Cristiano Gandini, MD,
Vincenzo Moschini, MD, and Thomas J. Smith, MD
Delta Research & Development (G.M.), Centro Ricerche Bioingegneria Medica, University of Rome
‘‘Tor Vergata,’’ Rome, Italy; Centro di Medicina del Dolore ‘‘Mario Tiengo’’ (V.I., C.G., V.M.), IRCCS
Fondazione Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena, Milan, Italy; and
Division of Hematology/Oncology and Palliative Care (T.J.S.), Massey Cancer Center, Virginia
Commonwealth University, Richmond, Virginia, USA
Abstract
Context. Neuropathic pain is common, disabling, and often difficult to treat.
Objectives. To compare guideline-based drug management with Scrambler
therapy, a patient-specific electrocutaneous nerve stimulation device.
Methods. A clinical trial with patients randomized to either guideline-based
pharmacological treatment or Scrambler therapy for a cycle of 10 daily sessions
was performed. Patients were matched by type of pain including postsurgical
neuropathic pain, postherpetic neuralgia, or spinal canal stenosis. Primary
outcome was change in visual analog scale (VAS) pain scores at one month;
secondary outcomes included VAS pain scores at two and three months, pain
medication use, and allodynia.
Results. Fifty-two patients were randomized. The mean VAS pain score before
treatment was 8.1 points (control) and 8.0 points (Scrambler). At one month, the
mean VAS score was reduced from 8.1 to 5.8 (28%) in the control group, and from
8 to 0.7 points (91%) in the Scrambler group (P < 0.0001). At two and three
months, the mean pain scores in the control group were 5.7 and 5.9 points,
respectively, and 1.4 and 2 points in the Scrambler group, respectively (P < 0.0001).
More relapses were seen in polyradicular pain than monoradicular pain, but
retreatment and maintenance therapy gave relief. No adverse effects were observed.
Conclusion. In this pilot randomized trial, Scrambler therapy appeared to
relieve chronic neuropathic pain better than guideline-based drug
management. J Pain Symptom Manage 2011;-:-e-. 2011
